SAM supports the responsible research of compounds in marijuana for the development of medication that is consistent with the practice of responsible medicine. Please consider sharing these position statements released by several prominent medical societies.

American Society of Addiction Medicine: “ASAM asserts that cannabis, cannabis-based products, and cannabis delivery devices should be subject to the same standards that are applicable to other prescription medications and medical devices and that these products should not be distributed or otherwise provided to patients unless and until such products or devices have received marketing approval from the Food and Drug Administration. ASAM rejects smoking as a means of drug delivery since it is not safe. ASAM rejects a process whereby State and local ballot initiatives approve medicines because these initiatives are being decided by individuals not qualified to make such decisions.”

American Cancer Society: “The ACS is supportive of more research into the benefits of cannabinoids. Better and more effective treatments are needed to overcome the side effects of cancer and its treatment. The ACS does not advocate the use of inhaled marijuana or the legalization of marijuana.”

American Glaucoma Foundation:“Marijuana, or its components administered systemically, cannot be recommended without a long term trial which evaluates the health of the optic nerve,” said the editorial.“Although marijuana can lower IOP, its side effects and short duration of action, coupled with a lack of evidence that its use alters the course of glaucoma, preclude recommending this drug in any form for the treatment of glaucoma at the present time.”

National Multiple Sclerosis Society: “Although it is clear that cannabinoids have potential both for the management of MS symptoms such as pain and spasticity, as well as for neuroprotection, the Society cannot at this time recommend that medical marijuana be made widely available to people with MS for symptom management. This decision was not only based on existing legal barriers to its use but, even more importantly, because studies to date do not demonstrate a clear benefit compared to existing symptomatic therapies and because issues of side effects, systemic effects, and long-term effects are not yet clear.”

The American Academy of Pediatrics (AAP) The American Academy of Pediatrics (AAP) opposes “medical marijuana” outside the regulatory process of the US Food and Drug Administration. Notwithstanding this opposition to use, the AAP recognizes that marijuana may currently be an option for cannabinoid administration for children with life-limiting or severely debilitating conditions and for whom current therapies are inadequate. The AAP strongly supports research and development of pharmaceutical cannabinoids and supports a review of policies promoting research on the medical use of these compounds.

The American Medical Association (AMA) has called for more research on the subject,with the caveat that this “should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product.” Furthermore, AMA believes (1) cannabis is a dangerous drug and as such is a public health concern; (2) sale of cannabis should not be legalized.

American Society of Addiction Medicine. “Public Policy Statement on Medical Marijuana.” (2010).

American Cancer Society. “Should Medical Marijuana Be a Medical Option?” (March 27, 2014).

American Glaucoma Foundation. “Marijuana for Glaucoma – Patients Beware” (August 5, 2010).

American Psychiatry Association. “Position Statement on Marijuana as Medicine” (2009).

American Academy of Pediatrics. “The impact of Marijuana Policies on Youth: Clinical,Research, and Legal Update.” (March 20, 2015).

American Medical Association. “H-95.952 Cannabis for Medicinal Use” (2009).